⚕️ The information below is for educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro), liraglutide (Victoza), and dulaglutide (Trulicity) — are approved in India by CDSCO specifically for Type 2 diabetes and (in the case of semaglutide) obesity. They are not approved for Type 1 diabetes.
However, Indian endocrinologists increasingly prescribe GLP-1 agonists off-label to certain Type 1 diabetes patients. If your doctor has suggested this, or if you are considering asking them about it, this guide explains what the science says, what the risks are, and what you must monitor.
Consult your healthcare provider before starting any medication.
People with Type 1 diabetes may be offered GLP-1 agonists for one or more of the following reasons:
1. Weight management As insulin therapy causes weight gain, some Type 1 patients become overweight or obese over time. GLP-1 medications reduce appetite and can help achieve weight loss while on insulin.
2. Reducing insulin dose requirements GLP-1 agonists slow gastric emptying and blunt post-meal glucose spikes, which can reduce the amount of mealtime insulin needed.
3. Improving HbA1c In people with Type 1 diabetes who also have insulin resistance (sometimes called "double diabetes" or Type 3c), GLP-1 can improve overall glycaemic control.
4. Cardiovascular protection The cardiovascular benefits of GLP-1 agonists are relevant to Type 1 patients, who have high rates of heart disease.
Two major trials studied GLP-1 agonists specifically in Type 1 diabetes:
ADJUNCT ONE (liraglutide 1.8 mg + insulin in T1D):
ADJUNCT TWO (liraglutide 1.2 mg + insulin in T1D):
SUSTAIN trials with semaglutide in T1D (smaller studies):
The conclusion: GLP-1 works in Type 1 diabetes, but the benefit-risk balance is more complex than in Type 2 diabetes. Careful patient selection and intensive monitoring are essential.
In Type 2 diabetes, GLP-1 agonists are very low risk for hypoglycaemia on their own because they only stimulate insulin secretion when blood glucose is elevated.
In Type 1 diabetes, the risk is different. You still take exogenous insulin. As GLP-1 slows gastric emptying and reduces your post-meal glucose rise, your pre-programmed mealtime insulin dose may become too high relative to actual glucose absorption — causing hypoglycaemia.
What this means practically:
This is the most serious risk and the reason GLP-1 is not approved for Type 1 diabetes.
When you reduce insulin doses (because GLP-1 appears to be helping), you can inadvertently drop insulin too low. Unlike Type 2 patients, Type 1 patients cannot produce their own insulin at all — so any insulin deficiency can trigger DKA, even at relatively normal blood glucose levels (euglycaemic DKA).
Euglycaemic DKA is particularly dangerous because:
Warning signs of DKA to act on immediately:
If you are on GLP-1 for Type 1 diabetes, invest in a blood ketone meter. Urine ketone strips are not sufficient — they detect past ketones, not current. Blood ketone meters (Optium Neo available in India, approximately ₹2,000 for the meter; ₹80–120 per strip) give real-time readings.
No matter how well GLP-1 works, people with Type 1 diabetes cannot stop or dramatically reduce their insulin. GLP-1 does not stimulate beta cells (which are absent or destroyed in T1D). It works through different pathways — suppressing glucagon, slowing gastric emptying, reducing appetite. Insulin replacement remains essential.
Not every Type 1 patient should use GLP-1. Indian endocrinologists typically consider it in:
People who are generally not suitable:
Not all endocrinologists in India are familiar with GLP-1 use in Type 1 diabetes. This remains an off-label, specialist-level decision.
Ask your doctor specifically:
If your doctor is uncertain, ask for a referral to a tertiary diabetes centre. Major hospitals in Mumbai (AIIMS, KEM), Delhi (AIIMS, Sir Ganga Ram), Bangalore (Manipal, St John's), Chennai (Madras Diabetes Research Foundation), and Hyderabad (Care Hospitals) have specialists experienced in complex insulin management.
| Parameter | Frequency | Notes |
|---|---|---|
| Blood glucose | 4–6 times daily (CGM preferred) | More frequent than T2D monitoring |
| Blood ketones | Daily during dose initiation; whenever unwell | Blood meter required — not urine strips |
| HbA1c | Every 3 months | |
| Weight | Weekly | Track benefit |
| Blood pressure | Monthly | GLP-1 lowers BP; hypotension risk |
| Kidney function (eGFR, creatinine) | Every 6 months | GLP-1 affects fluid balance |
| Insulin doses | Adjust with doctor every 2–4 weeks during initiation |
Q: Will GLP-1 cure or fix my Type 1 diabetes?
No. GLP-1 is an adjunct — it helps manage weight and some aspects of glucose control but does not replace insulin or address the autoimmune process underlying T1D.
Q: Can I use a CGM and GLP-1 together?
Yes, and in Type 1 diabetes, CGM (FreeStyle Libre 2, Dexcom G6/G7 — both available in India) is strongly encouraged when starting GLP-1. The real-time glucose trends help you and your doctor make safer insulin adjustments.
Q: My doctor said GLP-1 is only for Type 2. Is this wrong?
Your doctor is technically correct that GLP-1 is not approved for Type 1 in India. However, off-label use is legal and practised in specialised centres. If you believe GLP-1 could benefit you, ask for a second opinion from a diabetes specialist at a tertiary centre.
Q: Will GLP-1 cause hypoglycaemia if I forget to eat?
In Type 1 diabetes, hypoglycaemia risk comes from insulin, not GLP-1 directly. However, because GLP-1 slows gastric emptying, food absorption is delayed — so if you have taken mealtime insulin expecting food to arrive quickly and then cannot eat, hypoglycaemia can occur sooner than expected. Plan meals carefully.
